New hope for SMA: yearly injection aims to boost motor function
NCT ID NCT07444476
First seen Mar 21, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This study tests a drug called salanersen in people aged 15 to 60 with spinal muscular atrophy (SMA). The drug is designed to help the body produce more of a protein needed for muscle and nerve function. Participants receive an injection once a year for up to 5 years, and researchers will track changes in movement and daily activities. The study includes both people who have never been treated for SMA and those who have taken the drug risdiplam.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Childrens Hospital of the Kings Daughter Norfolk
RECRUITINGNorfolk, Virginia, 23507, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.